5n-Butyl-2-[2-chloro-5-(methoxycarbonyl)phenyl]-2,4-dihydro-3H-1,2,4-triazol-3-one | 147776-48-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5n-Butyl-2-[2-chloro-5-(methoxycarbonyl)phenyl]-2,4-dihydro-3H-1,2,4-triazol-3-one
• 英文别名: 5-n-butyl-2-(5-carbomethoxy-2-chlorophenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one；5-n-Butyl-2-[5-(carbomethoxy)-2-chlorophenyl)-2,4,dihydro-3H-1,2,4-triazol-3-one；5-n-Butyl-2-[2-chloro-5-(methoxycarbonyl)phenyl]-2,4-dihydro-3H-1,2,4-triazol-3-one；methyl 3-(3-butyl-5-oxo-4H-1,2,4-triazol-1-yl)-4-chlorobenzoate
• CAS: 147776-48-5
• 化学式: C₁₄H₁₆ClN₃O₃
• 分子量: 309.752
• InChiKey: YVAFKBKXAJHJTI-UHFFFAOYSA-N

物化性质

• 密度：
  1.34±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  71
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5n-Butyl-2-[2-chloro-5-(methoxycarbonyl)phenyl]-2,4-dihydro-3H-1,2,4-triazol-3-one 在 sodium hydroxide 、 sodium hydride 、 苯甲醚 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三氟乙酸 作用下， 以 四氢呋喃 为溶剂， 反应 26.5h， 生成 5-n-butyl-2-(5-carboxy-2-chlorophenyl)-4-<<2'-biphenyl-4-yl>methyl>-2,4-dihydro-3H-1,2,4-triazol-3-one
  参考文献：
  名称：

  Triazolinone Biphenylsulfonamides as Angiotensin II Receptor Antagonists with High Affinity for Both the AT1 and AT2 Subtypes

  摘要：

  Angiotensin II (AII), the endogenous peptide Ligand of the AII receptor, has equivalent high affinity for both the AT(1) and AT(2) receptor subtypes while most of the reported nonpeptide AII antagonists are AT(1)-selective. In an effort to identify dual AT(1)/AT(2) nonpeptide AII antagonists, we have pursued modifications of previously prepared trisubstituted 1,2,4-triazolinone biphenylsulfonamides which exhibited subnanomolar in vitro AT(1) (rabbit aorta) AII antagonism and AT(2) (rat midbrain) IC50 values of <40 nM. Present results show that a suitable amide (or reversed amide) side chain appropriately positioned on the N-2-aryl group of these compounds gave >15-fold enhancement in AT(2) binding affinity without sacrificing nanomolar AT(1) potency (IC50). This added amide, combined with an appropriate choice of the N-substituent on the sulfonamide and the ortho substituent on the N-2-aryl group, led to an analogue (46, L-163,- 007) which exhibited subnanomolar AT(1) binding affinity and an AT(2)/AT(1) IC50 ratio of 3. This compound showed excellent iv activity at 1 mg/kg and oral efficacy at 3 mg/kg with >6 h duration in a conscious rat model. Available data suggest that the newly introduced amide side chain, mandatory for low nanomolar binding affinity at the AT(2) receptor, is well-tolerated by the AT(1) receptor and has minimal effect on the in vivo properties of these molecules.

  DOI：

  10.1021/jm00052a006
• 作为产物：
  描述：

  5-(carbomethoxy)-2-chlorophenylhydrazine 以 CH2 Cl2 -MeOH 为溶剂， 以37%的产率得到5n-Butyl-2-[2-chloro-5-(methoxycarbonyl)phenyl]-2,4-dihydro-3H-1,2,4-triazol-3-one
  参考文献：
  名称：

  Substituted 1,2,4-triazoles bearing acidic functional groups as

  摘要：

  这些公式I中的新型替代三唑酮，三唑硫酮和三唑亚胺化合物可用作抗血管紧张素II拮抗剂。

  公开号：

  US05281614A1

文献信息

• Substituted triazolinones, triazolinethiones, and triazolinimines as
  申请人：Merck & Co., Inc.

  公开号：US05411980A1

  公开（公告）日：1995-05-02

  There are disclosed new substituted triazolinone, triazolinethione, and triazolinimine compounds which are useful as angiotensin II antagonists. These compounds have the general formula: ##STR1## wherein G is R.sup.1 or ##STR2##

  已披露了新的取代三唑酮，三唑硫酮和三唑亚胺化合物，这些化合物可用作血管紧张素II拮抗剂。这些化合物具有一般式：##STR1## 其中G为R.sup.1或##STR2##
• Potent and orally active angiotensin II receptor antagonists with equal affinity for human AT1 and AT2 subtypes
  作者：Linda L. Chang、Wallace T. Ashton、Kelly L. Flanagan、Tsing-Bau Chen、Stacey S. O'Malley、Gloria J. Zingaro、Salah D. Kivlighn、Peter K. S. Siegl、Victor J. Lotti

  DOI：10.1021/jm00019a004

  日期：1995.9

  induced by the interactions between angiotensin II (AII) and both AT1 and AT2 receptors, we have pursued the discovery of orally active non-peptide AII antagonists that exhibit potent and equal affinity for human AT1 and AT2 receptor subtypes. A series of previously prepared nanomolar (IC50) trisubstituted 1,2,4-triazolinone biphenyl-sulfonamide dual-acting AII antagonists has been modified at five different

  为了阻止由血管紧张素II（AII）与AT1和AT2受体之间的相互作用引起的影响，我们一直致力于发现对人AT1和AT2受体亚型表现出同等效力的口服活性非肽AII拮抗剂。一系列先前制备的纳摩尔（IC50）三取代的1,2,4-三唑啉酮联苯磺酰胺双作用AII拮抗剂已在五个不同位置进行了修饰，以增加AT2结合亲和力，维持AT1活性并降低人肾上腺AT2 / AT1效能比（IC50比率）≥10。使用多种在三唑啉酮的C5处具有乙基且在N4处具有3-氟取代基的化合物，可以达到目标的人肾上腺效能比<或= 1。 -联芳基甲基部分。这些化合物中最受青睐的化合物44在AT1（兔主动脉）和AT2（大鼠中脑）受体上均表现出亚纳摩尔效价，对后者稍有偏爱，人肾上腺AT2 / AT1 IC50比率为1。具有N2- [2-溴-5-（戊酰氨基）苯基]取代基的叔丁基磺酰基氨基甲酸酯在1 mg / kg时具有出色的iv活性（100％峰抑制，作用时间≥4
• Substituted triazolinones
  申请人：MERCK & CO. INC.

  公开号：EP0526001A1

  公开（公告）日：1993-02-03

  Substituted triazolinone compounds are angiotensin II antagonists and therefore useful in the treatment of hypertension, and related cardiovascular disorders and ocular hypertension. These compounds have the general formula:

  取代的三唑啉酮化合物是血管紧张素 II 拮抗剂，因此可用于治疗高血压、相关心血管疾病和眼压过高。这些化合物的通式如下
• US5281614A
  申请人：——

  公开号：US5281614A

  公开（公告）日：1994-01-25
• US5411980A
  申请人：——

  公开号：US5411980A

  公开（公告）日：1995-05-02